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Abstract: Preoperative chemoradiotherapy (CRT) is the standard of
care for patients with stage II and III rectal cancer. This strategy leads to
pathologic complete response (pCR) in a significant number of patients.
Factors predictive of pCR are currently being extensively investigated.
The aim of this study was to analyze clinical factors that might be
predictive of pCR.
This study was a retrospective analysis of rectal cancer patients from
January 2004 through December 2012. A total of 332 stage II and III
patients with middle and low rectal cancer (10 cm) who received CRT
and underwent curative total mesorectal excision were eligible. The
median radiation dose was 50.4Gy, and 72.6% of patients received
infusional 5-fluorouracil with leucovorin, whereas 19.6% of patients
received TS-1 with irinotecan, and 7.8% of patients received xeloda
only. Pathologic complete response was confirmed by using pathologic
specimens and analyzed based on predictive clinical factors.
Among the 332 patients, 27.4% (n¼ 91) achieved pCR. Age, sex,
body mass index, clinical T and N stages, tumor differentiation, the
chemotherapy agent for CRT, and the time interval between CRT and
surgery did not differ between the pCR and non-pCR groups. Carci-
noembryogenic antigen (CEA) levels before CRT were 4.61 7.38 ng/
mL in the pCR group and 10.49 23.83 ng/mL in the non-pCR group
(P¼ 0.035). Post-CRT CEA levels were 1.4 1.07 ng/mL in the pCR
group and 2.16 2.8 ng/mL in the non-pCR group (P¼ 0.014), and the
proportion of middle rectal cancer patients was higher in pCR group
(54.9%, P¼ 0.028). The results from multivariate logistic regression
analysis indicated that higher tumor location (odds ratio 2.151;
P¼ 0.003) and low post-CRT CEA level (odds ratio 0.789; P¼ 0.04)
were independent predictive factors for pCR.
Tumor location and post-CRT CEA level were predictive factors inPhD, Seung Hyuk ,
d Nam Kyu Kim, MD, PhD
(Medicine 94(45):e1971)
Abbreviations: CEA = carcinoembryogenic antigen, CRT =
chemoradiotherapy, pCR = pathologic complete response, TME =
total mesorectal excision.
INTRODUCTION
P reoperative chemoradiotherapy (CRT) followed by surgeryhas become the standard treatment for patients with stage II
and III rectal cancer, resulting in excellent local tumor control
and possibly improved long-term survival.1 Moreover, patho-
logic complete response(pCR) is often reported for specimens
obtained after CRT followed by surgery. Pathologic complete
response, defined as complete tumor regression with no viable
cancer cells in both primary tumors and regional lymph nodes,
is a remarkable finding, as it shows favorable results compared
with patients without pCR.2–5 It is also a critical issue for
determining the optimal management of rectal cancer after
CRT, in particular whether to perform surgery or not, as
pCR is defined as having no cancer.6 Several reports on breast
cancer treatment showed that responsiveness to preoperative
treatment is critical as it may predict clinical outcome and
increase breast conservation.7,8 Similarly, pCR can predict a
good outcome in rectal cancer patients; however, surgery must
be performed to confirm the presence of cancer, which can
provide accurate and definite staging, although one should
accept the risk of complications that may occur after surgery.
If the patient chooses a ‘‘wait and see’’ policy, which involves
declining surgery and relying on follow-up by observation, one
might avoid the potential risk of surgery; however, accurate
staging would not be available. Judging the tumor response
before surgery is not a simple issue, but a complex problem.
Although the disappearance of gross tumor after CRT has been
found to be highly correlated with pCR, residual disease in the
mesorectal lymph nodes has been reported in up to 17% of
patients.9 Therefore, the discovery of relevant clinical markers
for predicting pCR is an important issue. The aim of this study
was to determine any differences in clinical factors that might
occur between pCR and non-pCR groups after CRT in order for
physicians to better predict pCR.
METHODS
We performed a retrospective review of prospectively col-
lected records from the database of the Department of Surgery,
Yonsei University Health System, Seoul, South Korea from
January2004 toDecember2012. This study included 332patientsI or III rectal cancer as indicated by the
ve Cancer Network guidelines. These
followed by total mesorectal excision
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(TME). Strict selection criteriawere tumor location10 cm from
the anal verge, no concurrent benign ormalignant disease, and no
history of familial adenomatous polyposis or hereditary nonpo-
lyposis colorectal cancer. Upper rectal cancer with a tumor
location of more than 10 cm was excluded, as most of such
patients underwent surgery without CRT in our hospital. In total,
91of the 332patients comprised thepCRgroupand the remaining
241 patients comprised the non-pCR group. Pathologic complete
response was defined based on tumor regression and fibrotic
changes of pathologic specimen after CRT followed by surgery,
using a grading system adapted from Mandard et al.10
The initial clinical stage was based on digital rectal
examination, colonoscopy, endorectal ultrasound abdominal
computed tomography scan, and pelvic magnetic resonance
imaging. Tumor location was defined as the distance from
the caudal margin of the tumor to the anal verge, measured
by digital rectal examination, rigid proctoscopy, and pelvic
magnetic resonance imaging measurement. An anal verge of
less than 6 cm was defined as low rectal cancer and that of 6–
10 cm was defined as middle rectal cancer. Chemoradiotherapy
was administered to all patients with 3 types of chemotherapy
options, 5-fluorouracil with leucovorin, TS-1 (tegafur, gimer-
acil, and oteracil potassium capsule) with irinotecan or xeloda
only. 5-Fluorouracil was administered intravenously at a dose of
425mg/m2/d and leucovorin was also administered intrave-
Han et alnously at a dose of 20mg/m2/d during the first and fifth weeks
of radiotherapy. Five cycles of TS-1 and irinotecan were
administered during the radiotherapy. Irinotecan was given
TABLE 1. Patient, Tumor, and Treatment Characteristics
Variable
Sex
Age, y
Body mass index, kg/m2
American Society of Anesthesiologists
Pre-CRT carcinoembryogenic antigen, ng/mL
Post-CRT carcinoembryogenic antigen, ng/mL
Pretreatment clinical T stage
Pretreatment clinical N stage
Chemotherapy agent for CRT 5
Initial tumor differentiation
Tumor location (from anal verge)
Radiation dose, Gy
Time interval between CRT and surgery, d
CRT¼ chemoradiotherapy, SD¼ standard deviation.
2 | www.md-journal.comintravenously at a dose of 40mg/m2/d every once a week,
and TS-1 was administered orally at a dose of 70mg/m2/d
for 25 days during the radiation therapy period. Xeloda was
continuously administered orally at a dose of 1450mg/m2/d
twice daily during the radiation therapy period. Concurrent
pelvic radiation treatment with a median radiation dose of
50.4Gy (range 25–57.5Gy) was administered; 45Gy was
applied to the whole pelvis in 25 fractions for 5 weeks, followed
by 5.4Gy boosts on the gross tumor area for 3 days. All patients
underwent TME after the initial CRT. The time interval between
CRT and surgery was recorded from the end date of radio-
therapy to the day before surgery. Operations included low
anterior resection (n¼ 167), low anterior resection with coloa-
Medicine  Volume 94, Number 45, November 2015nal anastomosis (n¼ 107), and abdominoperineal resection
(n¼ 58). The study was approved by the institutional review
board of Severance Hospital (4-2015-0476).
Statistical Analysis
Data are summarized as frequencies and percentages for
categorical variables, and medians and ranges are used for
continuous variables. The x2 test was used to evaluate categ-
orical variables and Student’s t-test was used for continuous
variables. Multivariate analysis was performed using a logistic
regression model with factors shown to have an effect based on
univariate analysis. All other results were considered statisti-
cally significant if P< 0.05. We calculated receiver-operating
characteristic curves to validate the prediction power of the
Statistic Result (n¼ 332)
Male 228 (68.7%)
Female 104 (31.3%)
Median (range) 58 (27–85)
Mean (SD) 23.03 3.07
I 260 (78.3%)
II 66 (19.9%)
III and IV 6 (1.8%)
Mean (SD) 8.88 20.82
Mean (SD) 1.95 2.47
T2 16 (4.8%)
T3 236 (71.1%)
T4 80 (24.1%)
N0 91 (27.4%)
N1 188 (56.6%)
N2 53 (16%)
-Fluorouracilþ leucovorin 241 (72.6%)
Xeloda 26 (7.8%)
TS-1þ irinotecan 65 (19.6%)
Well 54 (16.3%)
Moderate 246 (74.1%)
Poor 11 (3.3%)
Mucinous 21 (6.3%)
Mean (SD) 5.735 2.45
Low (<6 cm) 182 (54.8%)
Middle (6–10 cm) 150 (45.2%)
Median (range) 50.4 (25–57.5)
Mean (SD) 61 13.16
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
teristic curve was achieved after logistic regression model in
TABLE 2. Univariate Pathologic Complete Response Analysis
Variable Level
Pathologic Complete
Response (n¼ 91)
Nonpathologic Complete
Response (n¼ 241) P
Sex Male 60 (65.9%) 168 (69.7%) 0.508
Female 31 (34.1%) 73 (30.3%)
Age, y Mean (SD) 58 10.58 56.8 11.74 0.406
Body mass index, kg/m2 Mean (SD) 23.56 3.03 22.82 3.07 0.053
Pre-CRT
carcinoembryogenic
antigen, ng/mL
Mean (SD) 4.61 7.38 10.49 23.83 0.035
Post-CRT
carcinoembryogenic
antigen, ng/mL
Mean (SD) 1.4 1.07 2.16 2.8 0.014
Pretreatment clinical T
stage
T2 7 (7.7%) 9 (3.7%) 0.108
T3 68 (74.7%) 168 (69.7%)
T4 16 (17.6%) 64 (26.6%)
Pretreatment clinical N
stage
N0 27 (29.7%) 64 (26.6%) 0.624
N1 50 (54.9%) 138 (57.3%)
N2 14 (15.4%) 39 (16.2%)
Chemotherapy agent for
CRT
5-Fluorouracil þ leucovorin 61 (67.0%) 180 (74.7%) 0.157
Xeloda 8 (8.8%) 18 (7.5%)
TS-1þ irinotecan 22 (24.2%) 43 (17.8%)
Initial tumor differentiation Well 18 (19.8%) 36 (14.9%) 0.112
Moderate 67 (73.6%) 179 (74.3%)
Poor 3 (3.3%) 8 (3.3%)
Mucinous 3 (3.3%) 18 (7.5%)
Tumor location (from anal
verge)
Low (<6 cm) 41 (45.1%) 141 (58.5%) 0.028
Middle (6–10 cm) 50 (54.9%) 100 (41.5%)
Time interval between CRT
and surgery, d
Mean (SD) 62.97 11.56 60.25 13.66 0.097
Medicine  Volume 94, Number 45, November 2015 Predicting Pathologic Complete Response in Rectal Cancerlogistic regression model. Statistical Package for the Social
Sciences for Windows (version 20.0, Chicago, IL) was used for
statistical analyses.
RESULTS
Clinical and pathologic characteristics of the population
are described in Table 1. The median age was 58 years (range
27–85) and the number of men was 228 (68.7%). Among the
322 patients, 91 (27.4%) were confirmed to have pCR on
pathologic specimen analysis after surgery. In comparing the
characteristics of patients in the pCR and non-pCR groups,
no statistically significant differences were found in age
(P¼ 0.407), sex (P¼ 0.508), and American Society of Anesthe-
siologists class score (P¼ 0.093). Body mass index, however,
was slightly higher in the pCR group (P¼ 0.053).
Clinical factors predicting pCR by univariate analysis are
presented in Table 2. Carcinoembryogenic antigen levels before
CRT were 4.61 7.38 ng/mL in the pCR group and
10.49 23.83 ng/mL in the non-pCR group (P¼ 0.035).
Post-CRT CEA levels were 1.4 1.07 ng/mL in the pCR group
CRT¼ chemoradiotherapy, SD¼ standard deviation.and 2.16 2.8 ng/mL in the non-pCR group (P¼ 0.014), and
the proportion of middle rectal cancer patients was higher in the
pCR group (54.9%, P¼ 0.028). Other variables (age, sex, body
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.mass index, pretreatment clinical T stage, initial tumor differ-
entiation, pretreatment clinical N stage, time interval between
CRT and surgery, and type of chemotherapy) showed no
statistical differences between the two groups. Although stat-
istically significant, pre-CRT CEA was to be excluded from
multivariable analysis, as it had been obtained before CRT and
was thus representative of the initial cancer rather than pCR.
Multicollinearity between pre-CRT CEA and post-CRT
CEA, however, indicated a low variance inflation factor
(VIF¼ 1.449), thus, all factors were acceptable for inclusion
in the multivariable analysis Table 3 shows tumor location
(P¼ 0.003) and post-CRT CEA level (P¼ 0.04) as significant
factors in multivariable logistic regression analysis, after apply-
ing effective variables with P value of less than 0.05 from
univariable analysis. An acceptable receiver-operating charac-Figure 1. The area under curve was 0.638, which indicated that
the model was acceptable for predicting pCR.DISCUSSION
Recently, there has been considerably more interest in
devising a method to predict pCR before undertaking surgery,
www.md-journal.com | 3
TABLE 3. Multivariate Analysis of Variables Significant in
Univariate Analysis for Pathologic Complete Response
Multivariate
Variables
Odds
Ratio
95% Confidence
Interval P
Postchemoradiotherapy
carcinoembryogenic
antigen
0.789 0.629–0.990 0.04
Tumor location 2.151 1.290–3.585 0.003
Prechemoradiotherapy
carcinoembryogenic
0.120
Han et alnot only in the colorectal field but also in many other surgical
fields. Physicians have investigated a variety of variables to find
clinical factors that are predictive of pCR, such as tumor
subtypes in breast cancer; biomarkers, serum CEA level,
macroscopic ulceration status, and tumor circumference in
rectal cancer; and smoking habits and tumor length in esopha-
geal cancer.11–14 A definite prediction of pCR is important, as a
recent study showed that tumor regression of near-pCR with
ypT3 or ypN1/2 in rectal cancer is associated with poor clinical
outcome.15 Moreover, performing surgery only to find a non-
viable tumor creates unnecessary risk in terms of morbidity
and mortality.
We found that post-CRT, CEA level and tumor location
were significant factors associated with pCR. Carcinoembryo-
antigengenic antigen is the most widely used serum marker for surveil-
lance, particularly after colorectal cancer surgery, to monitor for
recurrence. In addition, in rectal cancer, postoperative decrease in
FIGURE 1. Receiver-operating characteristic curve. Area under
curve¼0.638 (95%confidence interval, 0.571–0.705),P<0.001.
4 | www.md-journal.comthe CEA level has been found to be related to survival improve-
ment.16 Thus, several studies have used this simple tool to predict
pCR, and low serumCEA level has been reported as a significant
factor associatedwithpCR.17–19Basedon the results of our study,
a low post-CRT CEA level was associated with pCR. Pre-CRT
CEA may therefore be more indicative of tumor biologic status
than the response to CRT. Recently, Kleiman et al20 similarly
reported that normalization of CEA level after CRT showed
predictive value for pCR. In addition, Perez et al21 showed that
CEA levels of less than5 ng/dLwere predictive for pCRaswell as
5-year overall survival. There, however, is still some debate over
whether pre-CRT CEA, post-CRT CEA, or even both, are pre-
dictive.22,23 We did not analyze the change between post-CRT
CEA and postoperative CEA; however, the pCR group had a
lower post-CRT CEA level than the non-pCR group, which may
account for themarked reduction in theCEAlevel of thenon-pCR
group after CRT.
Interestingly, our results indicated a middle tumor level as
a predictor for pCR in multivariable analysis. Most previous
reports do not report tumor height as a significant factor
associated with pCR. There is no definite borderline for tumor
height that divides rectal cancer between low and high. Some
consider tumors 5 to 6 cm above the anal verge to be low rectal
cancer, although classification remains arbitrary.24,1 There is
debate as to whether upper rectal cancer patients should undergo
CRT before surgery or not, as they show lower local recurrence
rates than those with middle or low rectal cancer, and certain
reports also demonstrated no local recurrence differences
between CRT and non-CRT groups in upper rectal cancer.1,25,26
Accordingly, a low tumor location may increase the risk of local
recurrence in postradiation status.27 Kapiteijn et al1 reported a
1% 2-year local recurrence rate in a radiotherapy with surgery
group with tumor locations in the range of 5 to 10 cm, and a
10.1% recurrence rate in a surgery alone group with the
same tumor locations; conversely a 5.8% 2-year local recur-
rence rate was found in the radiotherapy with surgery group
with tumor locations at less than 5 cm, and a 10.0% recurrence
rate was found in the surgery alone group with the same
tumor locations. In addition, Das28 et al reported that a tumor
distance from the anal verge of more than 5 cm was indepen-
dently predictive of tumor downstaging. From a Dutch
rectal trial, middle rectal cancer showed lower local recurrence
rate after short-course radiotherapy followed by TME than after
TME alone.25 Although these reports do not completely
explain rectal cancer pCR in terms of tumor location, they
are based on the expected effects of radiotherapy, such as tumor
or lymph nodes sterilization; thus, a mid-level tumor
Medicine  Volume 94, Number 45, November 2015location may be the most effective radiation field for rectal
cancer. Further studies, however, are needed to confirm our
findings.
CONCLUSIONS
Given its retrospective nature, our study had several
limitations. First, there were no genetic data or biologic markers
with relevant clinical variables. There were also several reports
demonstrating that epidermal growth factor receptor and vas-
cular endothelial growth factor expression predicted decreased
pCR after CRT. The addition of such clinical data may have
enriched our results when predicting pCR. Second, as these
results were derived from a single institution, further prospec-
tive studies are necessary to fully evaluate the predictive factors
for pCR in rectal cancer.
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